Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 7/20 | 0.60 |
| ▸ | TNF | P01375 | 3/20 | 0.60 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.60 |
| ▸ | BRD4 | O60885 | 1/20 | 0.60 |
| ▸ | IL1B | P01584 | 1/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.60 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585976 | 0.88 | CRBN (0.67) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL19585563 | 0.84 | CRBN (0.55) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL23105166 | 0.80 | CRBN (0.65) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL21855349 | 0.79 | CRBN (0.74) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL1097880 | 0.79 | CRBN (1.00) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL31727916 | 0.79 | CRBN (1.00) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL20442491 | 0.79 | CRBN (1.00) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL29453150 | 0.79 | CRBN (1.00) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL31076618 | 0.78 | CRBN (0.71) | CRBNIKZF3TNFIKZF1BRD4 | |
| SCHEMBL25272444 | 0.78 | CRBN (0.71) | CRBNIKZF3TNFIKZF1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017197051-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |